Skip to search formSkip to main contentSkip to account menu

Pladienolide Derivative E7107

Known as: E7107 
A synthetic urethane derivative of pladienolide D with potential antineoplastic activity. Pladienolide derivative E7107 is generated from the 12… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
PO-445 E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes
Introduction Recent studies indicate that E7107, a spliceosome inhibitor, causes altered splicing of key genes in CLL. We… 
2017
2017
Abstract 420: Preclinical evaluation of the SF3B1 inhibitor E7107 in triple negative breast cancer
Triple-negative breast cancers (TNBC) are the most aggressive subtype of breast cancer and account for roughly 15% of human… 
2016
2016
First-in-human clinical, pharmacokinetic (PK), and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to…
3508 Background: E7107 is a potent first-in-class inhibitor of the spliceosome, most likely by interacting with spliceosome… 
2016
2016
Abstract 3013: Identification of PHF5A as a common cellular target of splicing-modulating chemical probes
Recent discoveries that splicing factors such SF3B1, U2AF1, SRSF2 are frequently mutated in multiple hematological malignancies… 
2015
2015
Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis
Mutations in the spliceosomal genes SRSF2 , U2AF1 and SF3B1 are commonly found in patients with myeloid malignancies including… 
2014
2014
Asymmetric synthesis of C11-C23 fragment of Pladienolide B
Synthesis of C11-C23 fragment of an antitumor natural product, Pladienolide B, in gram-scale, is described. The key steps… 
2013
2013
Cancer Therapy : Clinical See related article by Dehm , p . 6064 Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E 7107 in Patients with Advanced Solid…
Purpose: To assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of E7107 administered as 5… 
2009
2009
Abstract C32: First‐in‐human clinical, pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of the first‐in‐class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every…
Background: E7107 is a first‐in‐class inhibitor of the spliceosome, most likely by interacting with spliceosome‐associated… 
2007
2007
E7107: Antitumor activity on human SCLC and cervical cancer xenografts in relation to its potential predictive markers of response.
5608 E7107 is a semisynthetic derivative of pladienolide B, originally isolated from the fermented broth of Streptomyces… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)